Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04716712 · ClinicalTrials.gov registry record · Phase 4
Infant Mortality Reduction by the Mass Administration of Azithromycin
A Phase 4 study of Child Mortality, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 4
- Development phase
- 694,400
- Enrollment target
- 3
- Study locations
NCT04716712 is a Phase 4 study of Child Mortality that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 694,400 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT04716712, a Phase 4 study of Child Mortality, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 694,400 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azithromycin
Study Locations (3)
Other
- Centre de Recherche en Sante de Nouna - Nouna
- Helen Keller International - Ouagadougou
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 694,400 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04716712
The ClinicalTrials.gov registry entry for NCT04716712 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 694,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Child Mortality appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04716712 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT04716712 about?
NCT04716712 is a clinical study titled "Infant Mortality Reduction by the Mass Administration of Azithromycin". This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among chi...
What is the current status of trial NCT04716712?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 694,400 participants. The study started on 2021-10-04. Estimated completion is 2026-01-30.
What conditions does trial NCT04716712 study?
This clinical trial studies the following conditions: Child Mortality.
What interventions are being tested in trial NCT04716712?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT04716712?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04716712 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.